Raymond Woo, Ph.D., serves as Chief Technology Officer at Ceribell Inc., a neurotechnology leader in point-of-care EEG systems for rapid seizure detection and neurological monitoring. With a Ph.D. in Biomedical Engineering from Stanford University and over 25 years in medical device innovation, Dr. Woo has built a distinguished career bridging signal processing, wearable technology, and clinical diagnostics. His early work at Philips Healthcare and Intuitive Surgical honed his expertise in real-time data analytics and FDA-regulated product development, where he spearheaded algorithms for minimally invasive imaging systems. Dr. Woo's achievements include authoring more than 40 peer-reviewed publications in journals such as IEEE Transactions on Biomedical Engineering and holding 15 U.S. patents related to EEG signal enhancement and artifact rejection. Notable contributions encompass developing adaptive noise-cancellation techniques that improved diagnostic accuracy in noisy clinical environments, earning him the IEEE EMBS Early Career Achievement Award in 2010. Prior to Ceribell, he led R&D at NeuroPace, advancing implantable neurostimulation devices for epilepsy management. At Ceribell, Dr. Woo oversees the technology roadmap for the Ceribell System, a revolutionary 10-channel wearable EEG platform that enables clinicians to detect non-convulsive status epilepticus in under an hour. Under his leadership, the company has achieved multiple FDA clearances, expanded AI-driven analytics, and scaled production to support over 200 U.S. hospitals, significantly reducing time-to-diagnosis and improving patient outcomes in ICUs.